2025-07-26から1日間の記事一覧
OPTIMA: a phase II dose and volume de-escalation trial for human papillomavirus-positive oropharyngeal cancer.Seiwert TY, Foster CC, Blair EA, et al. Ann Oncol. 2019 Feb 1;30(2):297-302. DOI: 10.1093/annonc/mdy522. PMID: 30481287. 【背景と…
Neoadjuvant Nivolumab Plus Chemotherapy Followed By Response-Adaptive Therapy for HPV+ Oropharyngeal Cancer: OPTIMA II Phase 2 Open-Label Nonrandomized Controlled Trial.Rosenberg AJ, Agrawal N, Juloori A, et al. JAMA Oncol. 2024 Jul 1;10(7…
Neoadjuvant Nivolumab Plus Chemotherapy Followed by Response-Stratified Chemoradiation Therapy in HPV-Negative Head and Neck Cancer: The DEPEND Phase 2 Nonrandomized Clinical Trial. Rosenberg AJ, Juloori A, Jelinek MJ, et al. JAMA Oncol. 2…
ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial.Marvaso G, Corrao G, Zaffaroni M, et al. Lancet Oncol. 2025 Mar;26(3):300-311. DOI: 10.1016/S1…
Durvalumab and tremelimumab plus local partial tumour ablation (radiofrequency ablation or stereotactic radiotherapy) in patients with unresectable liver metastases from metastatic colorectal cancer: results of the EORTC-1560-GITCG multice…
Long-Term Survival Analysis of Neoadjuvant Chemoradiotherapy Versus Adjuvant Chemoradiotherapy for Locally Advanced Low Rectal Cancer.Chen S, Wu R, Wan J, et al. Cancer Med. 2025 Aug;14(15):e71042. DOI: 10.1002/cam4.71042. PMID: 40709606. …
Modified Target Delineation and Moderately Hypofractionated Radiotherapy for High-Grade Glioma: A Randomized Clinical Trial. Zhong L, Zhou P, Chen L, et al. JAMA Netw Open. 2025 Jul 1;8(7):e2523053. DOI: 10.1001/jamanetworkopen.2025.23053.…
Reconsidering palliative radiotherapy in addition to PD-1 blockade for non-small cell lung cancer: results from the FORCE phase II trial (AIO/YMO-TRK-0415).Bozorgmehr F, Chung I, Fischer JR, et al. Clin Exp Metastasis. 2025 Jul 24;42(5):42…
